organization · Reporting owner
Lux Ventures V, L.P.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eikon Therapeutics, Inc.EIKN · Entity 5380 | 10% owner | February 04, 2026 | February 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eikon Therapeutics, Inc.
Report date February 04, 2026 · Filed February 06, 2026
Jointly reported with Lux Venture Partners V, LLC, Wolfe Josh, Hebert Peter, Lux Co-Invest Opportunities II, L.P., Lux Total Opportunities, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 138,888 |
Reported balance
After 2026-02-04 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-02-04 · Purchase · Acquired 138,888 · Balance 138,888 F1: These shares are held by Lux Co-Invest Opportunities II, L.P. ("LCIO II"). Lux Co-Invest Partners II, LLC ("LCIP II") is the general partner of LCIO II and exercises voting and dispositive power over the shares noted herein held by LCIO II. Peter Hebert and Josh Wolfe, a member of the Issuer's board of directors (the "Individual Lux Managers"), are the individual managing members of LCIP II. The Individual Lux Managers, and as the sole managers of LCIP II, may be deemed to beneficially own the shares held by LCIO II. Each of LCIP II and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 138,888 |
Reported balance
After 2026-02-04 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2026-02-04 · Purchase · Acquired 138,888 · Balance 138,888 F2: These shares are held by Lux Total Opportunities, L.P. ("LTO"). Lux Total Opportunities Partners, LLC ("LTOP") is the general partner of LTO and exercises voting and dispositive power over the shares noted herein held by LTO. The Individual Lux Managers are the individual managing members of LTOP. The Individual Lux Managers, as the sole managers of LTOP, may be deemed to beneficially own the shares held by LTO. Each of LTOP and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,387,705 |
Reported balance
After 2026-02-06 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2026-02-06 · Conversion · Acquired 2,387,705 · Balance 2,387,705 F3: The Series A Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") on a 1-for-7.4578 basis and had no expiration date. F4: The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F5: These shares are held by Lux Ventures V, L.P. ("LVV"). Lux Venture Partners V, LLC ("LVPV") is the general partner of LVV and exercises voting and dispositive power over the shares noted herein held by LVV. The Individual Lux Managers are the individual managing members of LVPV. The Individual Lux Managers, as the sole managers of LVPV, may be deemed to beneficially own the shares held by LVV. Each of LVPV and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,290,428 |
Reported balance
After 2026-02-06 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2026-02-06 · Conversion · Acquired 1,151,540 · Balance 1,290,428 F4: The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F6: The Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F7: The Series B-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F1: These shares are held by Lux Co-Invest Opportunities II, L.P. ("LCIO II"). Lux Co-Invest Partners II, LLC ("LCIP II") is the general partner of LCIO II and exercises voting and dispositive power over the shares noted herein held by LCIO II. Peter Hebert and Josh Wolfe, a member of the Issuer's board of directors (the "Individual Lux Managers"), are the individual managing members of LCIP II. The Individual Lux Managers, and as the sole managers of LCIP II, may be deemed to beneficially own the shares held by LCIO II. Each of LCIP II and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,294,653 |
Reported balance
After 2026-02-06 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2026-02-06 · Conversion · Acquired 2,155,765 · Balance 2,294,653 F6: The Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F7: The Series B-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F8: The Series C Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F9: The Series C-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F10: The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F2: These shares are held by Lux Total Opportunities, L.P. ("LTO"). Lux Total Opportunities Partners, LLC ("LTOP") is the general partner of LTO and exercises voting and dispositive power over the shares noted herein held by LTO. The Individual Lux Managers are the individual managing members of LTOP. The Individual Lux Managers, as the sole managers of LTOP, may be deemed to beneficially own the shares held by LTO. Each of LTOP and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-06 · Conversion · Disposed 10,000,000 · Balance 0 F3: The Series A Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") on a 1-for-7.4578 basis and had no expiration date. F5: These shares are held by Lux Ventures V, L.P. ("LVV"). Lux Venture Partners V, LLC ("LVPV") is the general partner of LVV and exercises voting and dispositive power over the shares noted herein held by LVV. The Individual Lux Managers are the individual managing members of LVPV. The Individual Lux Managers, as the sole managers of LVPV, may be deemed to beneficially own the shares held by LVV. Each of LVPV and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-06 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-06 · Conversion · Disposed 7,807,026 · Balance 0 F4: The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F5: These shares are held by Lux Ventures V, L.P. ("LVV"). Lux Venture Partners V, LLC ("LVPV") is the general partner of LVV and exercises voting and dispositive power over the shares noted herein held by LVV. The Individual Lux Managers are the individual managing members of LVPV. The Individual Lux Managers, as the sole managers of LVPV, may be deemed to beneficially own the shares held by LVV. Each of LVPV and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-06 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-02-06 · Conversion · Disposed 2,502,252 · Balance 0 F4: The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F1: These shares are held by Lux Co-Invest Opportunities II, L.P. ("LCIO II"). Lux Co-Invest Partners II, LLC ("LCIP II") is the general partner of LCIO II and exercises voting and dispositive power over the shares noted herein held by LCIO II. Peter Hebert and Josh Wolfe, a member of the Issuer's board of directors (the "Individual Lux Managers"), are the individual managing members of LCIP II. The Individual Lux Managers, and as the sole managers of LCIP II, may be deemed to beneficially own the shares held by LCIO II. Each of LCIP II and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-06 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-02-06 · Conversion · Disposed 796,380 · Balance 0 F6: The Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F1: These shares are held by Lux Co-Invest Opportunities II, L.P. ("LCIO II"). Lux Co-Invest Partners II, LLC ("LCIP II") is the general partner of LCIO II and exercises voting and dispositive power over the shares noted herein held by LCIO II. Peter Hebert and Josh Wolfe, a member of the Issuer's board of directors (the "Individual Lux Managers"), are the individual managing members of LCIP II. The Individual Lux Managers, and as the sole managers of LCIP II, may be deemed to beneficially own the shares held by LCIO II. Each of LCIP II and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-06 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-02-06 · Conversion · Disposed 530,920 · Balance 0 F6: The Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F2: These shares are held by Lux Total Opportunities, L.P. ("LTO"). Lux Total Opportunities Partners, LLC ("LTOP") is the general partner of LTO and exercises voting and dispositive power over the shares noted herein held by LTO. The Individual Lux Managers are the individual managing members of LTOP. The Individual Lux Managers, as the sole managers of LTOP, may be deemed to beneficially own the shares held by LTO. Each of LTOP and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein. |
| Series B-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-06 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-02-06 · Conversion · Disposed 5,289,322 · Balance 0 F7: The Series B-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F1: These shares are held by Lux Co-Invest Opportunities II, L.P. ("LCIO II"). Lux Co-Invest Partners II, LLC ("LCIP II") is the general partner of LCIO II and exercises voting and dispositive power over the shares noted herein held by LCIO II. Peter Hebert and Josh Wolfe, a member of the Issuer's board of directors (the "Individual Lux Managers"), are the individual managing members of LCIP II. The Individual Lux Managers, and as the sole managers of LCIP II, may be deemed to beneficially own the shares held by LCIO II. Each of LCIP II and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein. |
| Series B-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-06 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-02-06 · Conversion · Disposed 3,526,215 · Balance 0 F7: The Series B-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F2: These shares are held by Lux Total Opportunities, L.P. ("LTO"). Lux Total Opportunities Partners, LLC ("LTOP") is the general partner of LTO and exercises voting and dispositive power over the shares noted herein held by LTO. The Individual Lux Managers are the individual managing members of LTOP. The Individual Lux Managers, as the sole managers of LTOP, may be deemed to beneficially own the shares held by LTO. Each of LTOP and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-06 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-02-06 · Conversion · Disposed 303,360 · Balance 0 F8: The Series C Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F2: These shares are held by Lux Total Opportunities, L.P. ("LTO"). Lux Total Opportunities Partners, LLC ("LTOP") is the general partner of LTO and exercises voting and dispositive power over the shares noted herein held by LTO. The Individual Lux Managers are the individual managing members of LTOP. The Individual Lux Managers, as the sole managers of LTOP, may be deemed to beneficially own the shares held by LTO. Each of LTOP and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein. |
| Series C-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-06 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-02-06 · Conversion · Disposed 1,450,614 · Balance 0 F9: The Series C-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F2: These shares are held by Lux Total Opportunities, L.P. ("LTO"). Lux Total Opportunities Partners, LLC ("LTOP") is the general partner of LTO and exercises voting and dispositive power over the shares noted herein held by LTO. The Individual Lux Managers are the individual managing members of LTOP. The Individual Lux Managers, as the sole managers of LTOP, may be deemed to beneficially own the shares held by LTO. Each of LTOP and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-06 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-02-06 · Conversion · Disposed 10,266,152 · Balance 0 F10: The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F2: These shares are held by Lux Total Opportunities, L.P. ("LTO"). Lux Total Opportunities Partners, LLC ("LTOP") is the general partner of LTO and exercises voting and dispositive power over the shares noted herein held by LTO. The Individual Lux Managers are the individual managing members of LTOP. The Individual Lux Managers, as the sole managers of LTOP, may be deemed to beneficially own the shares held by LTO. Each of LTOP and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are held by Lux Co-Invest Opportunities II, L.P. ("LCIO II"). Lux Co-Invest Partners II, LLC ("LCIP II") is the general partner of LCIO II and exercises voting and dispositive power over the shares noted herein held by LCIO II. Peter Hebert and Josh Wolfe, a member of the Issuer's board of directors (the "Individual Lux Managers"), are the individual managing members of LCIP II. The Individual Lux Managers, and as the sole managers of LCIP II, may be deemed to beneficially own the shares held by LCIO II. Each of LCIP II and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein.
F2: These shares are held by Lux Total Opportunities, L.P. ("LTO"). Lux Total Opportunities Partners, LLC ("LTOP") is the general partner of LTO and exercises voting and dispositive power over the shares noted herein held by LTO. The Individual Lux Managers are the individual managing members of LTOP. The Individual Lux Managers, as the sole managers of LTOP, may be deemed to beneficially own the shares held by LTO. Each of LTOP and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein.
F3: The Series A Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") on a 1-for-7.4578 basis and had no expiration date.
F4: The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.
F5: These shares are held by Lux Ventures V, L.P. ("LVV"). Lux Venture Partners V, LLC ("LVPV") is the general partner of LVV and exercises voting and dispositive power over the shares noted herein held by LVV. The Individual Lux Managers are the individual managing members of LVPV. The Individual Lux Managers, as the sole managers of LVPV, may be deemed to beneficially own the shares held by LVV. Each of LVPV and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein.
F6: The Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.
F7: The Series B-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.
F8: The Series C Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.
F9: The Series C-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.
F10: The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 06, 2026 Filed Feb 6, 2026 18:25 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries D Preferred Stock · Derivative | 10,266,152 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-041544 · ownership.xml · derivative · entry 15 Lux Venture Partners V, LLC · CIK 0001698118 · 10% owner Wolfe Josh · CIK 0001830001 · Director · 10% owner Hebert Peter · CIK 0001683771 · 10% owner Lux Ventures V, L.P. · CIK 0001698008 · 10% owner Lux Co-Invest Opportunities II, L.P. · CIK 0001783916 · 10% owner Lux Total Opportunities, L.P. · CIK 0001864658 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,376,566 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F10 · price: The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F10 · derivative.exercise_date: The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F10 · derivative.expiration_date: The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F2 · ownership.nature: These shares are held by Lux Total Opportunities, L.P. ("LTO"). Lux Total Opportunities Partners, LLC ("LTOP") is the general partner of LTO and exercises voting and dispositive power over the shares noted herein held by LTO. The Individual Lux Managers are the individual managing members of LTOP. The Individual Lux Managers, as the sole managers of LTOP, may be deemed to beneficially own the shares held by LTO. Each of LTOP and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein. Read SEC document |
| February 06, 2026 Filed Feb 6, 2026 18:25 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries C-1 Preferred Stock · Derivative | 1,450,614 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-041544 · ownership.xml · derivative · entry 14 Lux Venture Partners V, LLC · CIK 0001698118 · 10% owner Wolfe Josh · CIK 0001830001 · Director · 10% owner Hebert Peter · CIK 0001683771 · 10% owner Lux Ventures V, L.P. · CIK 0001698008 · 10% owner Lux Co-Invest Opportunities II, L.P. · CIK 0001783916 · 10% owner Lux Total Opportunities, L.P. · CIK 0001864658 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 194,510 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: The Series C-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F9 · price: The Series C-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F9 · derivative.exercise_date: The Series C-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F9 · derivative.expiration_date: The Series C-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F2 · ownership.nature: These shares are held by Lux Total Opportunities, L.P. ("LTO"). Lux Total Opportunities Partners, LLC ("LTOP") is the general partner of LTO and exercises voting and dispositive power over the shares noted herein held by LTO. The Individual Lux Managers are the individual managing members of LTOP. The Individual Lux Managers, as the sole managers of LTOP, may be deemed to beneficially own the shares held by LTO. Each of LTOP and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein. Read SEC document |
| February 06, 2026 Filed Feb 6, 2026 18:25 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries C Preferred Stock · Derivative | 303,360 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-041544 · ownership.xml · derivative · entry 13 Lux Venture Partners V, LLC · CIK 0001698118 · 10% owner Wolfe Josh · CIK 0001830001 · Director · 10% owner Hebert Peter · CIK 0001683771 · 10% owner Lux Ventures V, L.P. · CIK 0001698008 · 10% owner Lux Co-Invest Opportunities II, L.P. · CIK 0001783916 · 10% owner Lux Total Opportunities, L.P. · CIK 0001864658 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 40,677 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: The Series C Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F8 · price: The Series C Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F8 · derivative.exercise_date: The Series C Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F8 · derivative.expiration_date: The Series C Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F2 · ownership.nature: These shares are held by Lux Total Opportunities, L.P. ("LTO"). Lux Total Opportunities Partners, LLC ("LTOP") is the general partner of LTO and exercises voting and dispositive power over the shares noted herein held by LTO. The Individual Lux Managers are the individual managing members of LTOP. The Individual Lux Managers, as the sole managers of LTOP, may be deemed to beneficially own the shares held by LTO. Each of LTOP and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein. Read SEC document |
| February 06, 2026 Filed Feb 6, 2026 18:25 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries B-1 Preferred Stock · Derivative | 3,526,215 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-041544 · ownership.xml · derivative · entry 12 Lux Venture Partners V, LLC · CIK 0001698118 · 10% owner Wolfe Josh · CIK 0001830001 · Director · 10% owner Hebert Peter · CIK 0001683771 · 10% owner Lux Ventures V, L.P. · CIK 0001698008 · 10% owner Lux Co-Invest Opportunities II, L.P. · CIK 0001783916 · 10% owner Lux Total Opportunities, L.P. · CIK 0001864658 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 472,822 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: The Series B-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F7 · price: The Series B-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F7 · derivative.exercise_date: The Series B-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F7 · derivative.expiration_date: The Series B-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F2 · ownership.nature: These shares are held by Lux Total Opportunities, L.P. ("LTO"). Lux Total Opportunities Partners, LLC ("LTOP") is the general partner of LTO and exercises voting and dispositive power over the shares noted herein held by LTO. The Individual Lux Managers are the individual managing members of LTOP. The Individual Lux Managers, as the sole managers of LTOP, may be deemed to beneficially own the shares held by LTO. Each of LTOP and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein. Read SEC document |
| February 06, 2026 Filed Feb 6, 2026 18:25 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries B-1 Preferred Stock · Derivative | 5,289,322 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-041544 · ownership.xml · derivative · entry 11 Lux Venture Partners V, LLC · CIK 0001698118 · 10% owner Wolfe Josh · CIK 0001830001 · Director · 10% owner Hebert Peter · CIK 0001683771 · 10% owner Lux Ventures V, L.P. · CIK 0001698008 · 10% owner Lux Co-Invest Opportunities II, L.P. · CIK 0001783916 · 10% owner Lux Total Opportunities, L.P. · CIK 0001864658 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 709,234 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: The Series B-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F7 · price: The Series B-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F7 · derivative.exercise_date: The Series B-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F7 · derivative.expiration_date: The Series B-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F1 · ownership.nature: These shares are held by Lux Co-Invest Opportunities II, L.P. ("LCIO II"). Lux Co-Invest Partners II, LLC ("LCIP II") is the general partner of LCIO II and exercises voting and dispositive power over the shares noted herein held by LCIO II. Peter Hebert and Josh Wolfe, a member of the Issuer's board of directors (the "Individual Lux Managers"), are the individual managing members of LCIP II. The Individual Lux Managers, and as the sole managers of LCIP II, may be deemed to beneficially own the shares held by LCIO II. Each of LCIP II and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein. Read SEC document |
| February 06, 2026 Filed Feb 6, 2026 18:25 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries B Preferred Stock · Derivative | 530,920 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-041544 · ownership.xml · derivative · entry 10 Lux Venture Partners V, LLC · CIK 0001698118 · 10% owner Wolfe Josh · CIK 0001830001 · Director · 10% owner Hebert Peter · CIK 0001683771 · 10% owner Lux Ventures V, L.P. · CIK 0001698008 · 10% owner Lux Co-Invest Opportunities II, L.P. · CIK 0001783916 · 10% owner Lux Total Opportunities, L.P. · CIK 0001864658 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 71,190 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: The Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F6 · price: The Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F6 · derivative.exercise_date: The Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F6 · derivative.expiration_date: The Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F2 · ownership.nature: These shares are held by Lux Total Opportunities, L.P. ("LTO"). Lux Total Opportunities Partners, LLC ("LTOP") is the general partner of LTO and exercises voting and dispositive power over the shares noted herein held by LTO. The Individual Lux Managers are the individual managing members of LTOP. The Individual Lux Managers, as the sole managers of LTOP, may be deemed to beneficially own the shares held by LTO. Each of LTOP and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein. Read SEC document |
| February 06, 2026 Filed Feb 6, 2026 18:25 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries B Preferred Stock · Derivative | 796,380 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-041544 · ownership.xml · derivative · entry 9 Lux Venture Partners V, LLC · CIK 0001698118 · 10% owner Wolfe Josh · CIK 0001830001 · Director · 10% owner Hebert Peter · CIK 0001683771 · 10% owner Lux Ventures V, L.P. · CIK 0001698008 · 10% owner Lux Co-Invest Opportunities II, L.P. · CIK 0001783916 · 10% owner Lux Total Opportunities, L.P. · CIK 0001864658 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 106,785 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: The Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F6 · price: The Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F6 · derivative.exercise_date: The Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F6 · derivative.expiration_date: The Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F1 · ownership.nature: These shares are held by Lux Co-Invest Opportunities II, L.P. ("LCIO II"). Lux Co-Invest Partners II, LLC ("LCIP II") is the general partner of LCIO II and exercises voting and dispositive power over the shares noted herein held by LCIO II. Peter Hebert and Josh Wolfe, a member of the Issuer's board of directors (the "Individual Lux Managers"), are the individual managing members of LCIP II. The Individual Lux Managers, and as the sole managers of LCIP II, may be deemed to beneficially own the shares held by LCIO II. Each of LCIP II and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein. Read SEC document |
| February 06, 2026 Filed Feb 6, 2026 18:25 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries A-1 Preferred Stock · Derivative | 2,502,252 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-041544 · ownership.xml · derivative · entry 8 Lux Venture Partners V, LLC · CIK 0001698118 · 10% owner Wolfe Josh · CIK 0001830001 · Director · 10% owner Hebert Peter · CIK 0001683771 · 10% owner Lux Ventures V, L.P. · CIK 0001698008 · 10% owner Lux Co-Invest Opportunities II, L.P. · CIK 0001783916 · 10% owner Lux Total Opportunities, L.P. · CIK 0001864658 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 335,521 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F4 · price: The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F4 · derivative.exercise_date: The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F4 · derivative.expiration_date: The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F1 · ownership.nature: These shares are held by Lux Co-Invest Opportunities II, L.P. ("LCIO II"). Lux Co-Invest Partners II, LLC ("LCIP II") is the general partner of LCIO II and exercises voting and dispositive power over the shares noted herein held by LCIO II. Peter Hebert and Josh Wolfe, a member of the Issuer's board of directors (the "Individual Lux Managers"), are the individual managing members of LCIP II. The Individual Lux Managers, and as the sole managers of LCIP II, may be deemed to beneficially own the shares held by LCIO II. Each of LCIP II and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein. Read SEC document |
| February 06, 2026 Filed Feb 6, 2026 18:25 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries A-1 Preferred Stock · Derivative | 7,807,026 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-041544 · ownership.xml · derivative · entry 7 Lux Venture Partners V, LLC · CIK 0001698118 · 10% owner Wolfe Josh · CIK 0001830001 · Director · 10% owner Hebert Peter · CIK 0001683771 · 10% owner Lux Ventures V, L.P. · CIK 0001698008 · 10% owner Lux Co-Invest Opportunities II, L.P. · CIK 0001783916 · 10% owner Lux Total Opportunities, L.P. · CIK 0001864658 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,046,827 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F4 · price: The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F4 · derivative.exercise_date: The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F4 · derivative.expiration_date: The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F5 · ownership.nature: These shares are held by Lux Ventures V, L.P. ("LVV"). Lux Venture Partners V, LLC ("LVPV") is the general partner of LVV and exercises voting and dispositive power over the shares noted herein held by LVV. The Individual Lux Managers are the individual managing members of LVPV. The Individual Lux Managers, as the sole managers of LVPV, may be deemed to beneficially own the shares held by LVV. Each of LVPV and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein. Read SEC document |
| February 06, 2026 Filed Feb 6, 2026 18:25 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries A Preferred Stock · Derivative | 10,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-041544 · ownership.xml · derivative · entry 6 Lux Venture Partners V, LLC · CIK 0001698118 · 10% owner Wolfe Josh · CIK 0001830001 · Director · 10% owner Hebert Peter · CIK 0001683771 · 10% owner Lux Ventures V, L.P. · CIK 0001698008 · 10% owner Lux Co-Invest Opportunities II, L.P. · CIK 0001783916 · 10% owner Lux Total Opportunities, L.P. · CIK 0001864658 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,340,878 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series A Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") on a 1-for-7.4578 basis and had no expiration date. F3 · price: The Series A Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") on a 1-for-7.4578 basis and had no expiration date. F3 · derivative.exercise_date: The Series A Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") on a 1-for-7.4578 basis and had no expiration date. F3 · derivative.expiration_date: The Series A Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") on a 1-for-7.4578 basis and had no expiration date. F5 · ownership.nature: These shares are held by Lux Ventures V, L.P. ("LVV"). Lux Venture Partners V, LLC ("LVPV") is the general partner of LVV and exercises voting and dispositive power over the shares noted herein held by LVV. The Individual Lux Managers are the individual managing members of LVPV. The Individual Lux Managers, as the sole managers of LVPV, may be deemed to beneficially own the shares held by LVV. Each of LVPV and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein. Read SEC document |
| February 06, 2026 Filed Feb 6, 2026 18:25 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionCommon Stock | 2,155,765 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-041544 · ownership.xml · nonDerivative · entry 5 Lux Venture Partners V, LLC · CIK 0001698118 · 10% owner Wolfe Josh · CIK 0001830001 · Director · 10% owner Hebert Peter · CIK 0001683771 · 10% owner Lux Ventures V, L.P. · CIK 0001698008 · 10% owner Lux Co-Invest Opportunities II, L.P. · CIK 0001783916 · 10% owner Lux Total Opportunities, L.P. · CIK 0001864658 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,294,653 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: The Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F7 · price: The Series B-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F8 · price: The Series C Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F9 · price: The Series C-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F10 · price: The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F2 · ownership.nature: These shares are held by Lux Total Opportunities, L.P. ("LTO"). Lux Total Opportunities Partners, LLC ("LTOP") is the general partner of LTO and exercises voting and dispositive power over the shares noted herein held by LTO. The Individual Lux Managers are the individual managing members of LTOP. The Individual Lux Managers, as the sole managers of LTOP, may be deemed to beneficially own the shares held by LTO. Each of LTOP and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein. Read SEC document |
| February 06, 2026 Filed Feb 6, 2026 18:25 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionCommon Stock | 1,151,540 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-041544 · ownership.xml · nonDerivative · entry 4 Lux Venture Partners V, LLC · CIK 0001698118 · 10% owner Wolfe Josh · CIK 0001830001 · Director · 10% owner Hebert Peter · CIK 0001683771 · 10% owner Lux Ventures V, L.P. · CIK 0001698008 · 10% owner Lux Co-Invest Opportunities II, L.P. · CIK 0001783916 · 10% owner Lux Total Opportunities, L.P. · CIK 0001864658 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,290,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F6 · price: The Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F7 · price: The Series B-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F1 · ownership.nature: These shares are held by Lux Co-Invest Opportunities II, L.P. ("LCIO II"). Lux Co-Invest Partners II, LLC ("LCIP II") is the general partner of LCIO II and exercises voting and dispositive power over the shares noted herein held by LCIO II. Peter Hebert and Josh Wolfe, a member of the Issuer's board of directors (the "Individual Lux Managers"), are the individual managing members of LCIP II. The Individual Lux Managers, and as the sole managers of LCIP II, may be deemed to beneficially own the shares held by LCIO II. Each of LCIP II and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein. Read SEC document |
| February 06, 2026 Filed Feb 6, 2026 18:25 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionCommon Stock | 2,387,705 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-041544 · ownership.xml · nonDerivative · entry 3 Lux Venture Partners V, LLC · CIK 0001698118 · 10% owner Wolfe Josh · CIK 0001830001 · Director · 10% owner Hebert Peter · CIK 0001683771 · 10% owner Lux Ventures V, L.P. · CIK 0001698008 · 10% owner Lux Co-Invest Opportunities II, L.P. · CIK 0001783916 · 10% owner Lux Total Opportunities, L.P. · CIK 0001864658 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,387,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The Series A Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") on a 1-for-7.4578 basis and had no expiration date. F4 · price: The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F5 · ownership.nature: These shares are held by Lux Ventures V, L.P. ("LVV"). Lux Venture Partners V, LLC ("LVPV") is the general partner of LVV and exercises voting and dispositive power over the shares noted herein held by LVV. The Individual Lux Managers are the individual managing members of LVPV. The Individual Lux Managers, as the sole managers of LVPV, may be deemed to beneficially own the shares held by LVV. Each of LVPV and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 18:25 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | PurchaseCommon Stock | 138,888 | $18.00 | $2,499,984.00 |
DisclosureSEC source: 0001193125-26-041544 · ownership.xml · nonDerivative · entry 2 Lux Venture Partners V, LLC · CIK 0001698118 · 10% owner Wolfe Josh · CIK 0001830001 · Director · 10% owner Hebert Peter · CIK 0001683771 · 10% owner Lux Ventures V, L.P. · CIK 0001698008 · 10% owner Lux Co-Invest Opportunities II, L.P. · CIK 0001783916 · 10% owner Lux Total Opportunities, L.P. · CIK 0001864658 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 138,888 F2 · ownership.nature: These shares are held by Lux Total Opportunities, L.P. ("LTO"). Lux Total Opportunities Partners, LLC ("LTOP") is the general partner of LTO and exercises voting and dispositive power over the shares noted herein held by LTO. The Individual Lux Managers are the individual managing members of LTOP. The Individual Lux Managers, as the sole managers of LTOP, may be deemed to beneficially own the shares held by LTO. Each of LTOP and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 18:25 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | PurchaseCommon Stock | 138,888 | $18.00 | $2,499,984.00 |
DisclosureSEC source: 0001193125-26-041544 · ownership.xml · nonDerivative · entry 1 Lux Venture Partners V, LLC · CIK 0001698118 · 10% owner Wolfe Josh · CIK 0001830001 · Director · 10% owner Hebert Peter · CIK 0001683771 · 10% owner Lux Ventures V, L.P. · CIK 0001698008 · 10% owner Lux Co-Invest Opportunities II, L.P. · CIK 0001783916 · 10% owner Lux Total Opportunities, L.P. · CIK 0001864658 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 138,888 F1 · ownership.nature: These shares are held by Lux Co-Invest Opportunities II, L.P. ("LCIO II"). Lux Co-Invest Partners II, LLC ("LCIP II") is the general partner of LCIO II and exercises voting and dispositive power over the shares noted herein held by LCIO II. Peter Hebert and Josh Wolfe, a member of the Issuer's board of directors (the "Individual Lux Managers"), are the individual managing members of LCIP II. The Individual Lux Managers, and as the sole managers of LCIP II, may be deemed to beneficially own the shares held by LCIO II. Each of LCIP II and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.